Condyloma acuminatum, caused by human papilloma virus (HPV) infection, is by far the most common sexually transmitted disease. Because of its strong recurrence, it imposes a significant emotional burden on this group of patients. Current studies have found that about 40 species of HPV can infect the human genital tract, and 90% of genital warts are clinically caused by low-risk HPV types such as HPV6,11. High-risk HPV types such as HPV 16 and 18 cause 70% of cervical cancers. In immunocompetent individuals, HPV often resolves within 2 years. Because small, invisible skin lesions can expose cells in the basal skin layer to HPV, some patients may have recurrent lesions that are difficult to eradicate due to unconscious self-inoculation. The goal of genital wart treatment is to remove the warts that are visible to the naked eye; however, it is often difficult to determine whether HPV has been cleared. The absence of ideal virucidal drugs for HPV has led to a diversity of treatments available for genital warts: physical destruction; cytotoxic drugs; and immunotherapy. Physical destruction includes the commonly used freezing, laser, and surgical excision. Cytotoxic drugs include high concentrations of trichloroacetic acid and onychotoxin. Immunotherapy includes interferon, imiquimod, and isotretinoin, and the 2010 FDA STD treatment guidelines emphasize the use of individualized treatment regimens with scientific, regular, and sequential follow-up for patients with genital warts. 5-Aminoketovaleric acid photodynamic therapy (ALA-PDT) is a non-invasive treatment based on the principles of photosensitizers and photocytotoxicity that has been adopted in recent years. The treatment principle includes :HPV infected skin cells are actively proliferating, exogenous ALA is ingested by HPV infected cells after wart application, and is converted into strong photosensitizers such as protoporphyrin IX in the cells, which generates reactive oxygen species and free radicals after specific wavelength and energy of light. This destroys the HPV infected tissues that are growing like crazy, while less reaction occurs in the surrounding normal tissues due to less absorption. Treatment of genital warts with photodynamic therapy is effective and recurrence is rare in most patients. The literature reports that after one to four treatments, the overall effectiveness rate for cervical and external genital warts is 98.2% and the HPV clearance rate is 83.9%. In addition it is the only treatment on the market that can act on latent and subclinical infections. Recent studies have shown that after photodynamic therapy, infiltration of immune cells (CD4T cells and dendritic cells) that facilitate the clearance of HPV by the body is seen within the warts of genital warts, thus helping to explain the unique long-term remission and less recurrence benefits of photodynamic therapy. The main adverse effects of photodynamic therapy treatment include tingling sensation during light exposure and increased vaginal discharge after cervical acromegaly treatment. Although not officially licensed for treatment in the pregnant patient population, it appears to be safe.